Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm, Residual 1 Lymphoproliferative Disorders 1 Lymphoma, B-Cell 1 Lymphoma 1 Lung Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1

Interventions

pembrolizumab 88 Carboplatin 77 Specimen Handling 76 Magnetic Resonance Spectroscopy 63 Pemetrexed 59 Cisplatin 47 durvalumab 44 Paclitaxel 38 Nivolumab 34 atezolizumab 32 osimertinib 29 Radiotherapy 29 Radiosurgery 29 Biopsy 26 Blood Specimen Collection 25 Gemcitabine 24 Docetaxel 24 Immunoglobulin G 23 Disulfides 22 Standard of Care 21 Drug Therapy 21 Etoposide 19 Taxes 18 Practice Guidelines as Topic 18 Radiation 17 Educational Status 16 130-nm albumin-bound paclitaxel 15 X-Rays 14 Surveys and Questionnaires 14 Bevacizumab 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Neoplasms × Biological Assay × 1 year × Clear all

NCT06716580 2025-12-10

EQUAL

Dana-Farber Cancer Institute

Phase NA Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡